Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14676 - 14700 of 15241 in total
BEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. It is under investigation for the treatment of glioblastoma.
Investigational
Matched Description: … BEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. …
Zandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).
Investigational
Matched Description: … Zandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and
Didesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their insecticidal benefits, this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of...
Experimental
Matched Description: … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of ... being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and
ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon. Releasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis.
Investigational
Investigational
Investigational
Experimental
Experimental
Experimental
Hydronidone has antifibrotic activity.
Investigational
Becatecarin is a derivative of rebeccamycin.
Investigational
Experimental
Experimental
Displaying drugs 14676 - 14700 of 15241 in total